4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds

Patent metadata

Field	Value
Publication number	US-10034870-B2
Application number	US-201715591419-A
Country	US
Kind code	B2
Filing date	May 10, 2017
Priority date	Nov 14, 2008
Publication date	Jul 31, 2018
Grant date	Jul 31, 2018

Abstract

The invention relates to compounds of formula I:

where a, R 1 , and R 3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

First claim

What is claimed is:

1. A method of inhibiting norepinephrine reuptake in a mammal, the method comprising administering to the mammal a norepinephrine transporter-inhibiting amount of a compound of the formula:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the compound is administered as a hydrochloride salt.

3. The method of claim 1 , wherein the mammal is a human.

4. A method of inhibiting norepinephrine reuptake in a mammal, the method comprising administering to the mammal a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a norepinephrine transporter-inhibiting amount of a compound of the formula:

or a pharmaceutically acceptable salt thereof.

5. The method of claim 4 , wherein the compound is administered as a hydrochloride salt.

6. The method of claim 4 , wherein the mammal is a human.

7. The method of claim 4 , wherein the pharmaceutical composition contains about 1 milligram to about 20 milligrams of the compound or a pharmaceutically acceptable salt thereof.

8. The method of claim 4 , wherein the pharmaceutical composition contains about 1 milligram to about 15 milligrams of the compound or a pharmaceutically acceptable salt thereof.

9. The method of claim 4 , wherein the pharmaceutical composition contains about 1 milligram to about 10 milligrams of the compound or a pharmaceutically acceptable salt thereof.

10. The method of claim 4 , wherein the pharmaceutical composition is administered orally.

Assignees

• Theravance Biopharma R&D Ip Llc

Inventors

• Patterson Lori Jean
• Stangeland Eric L

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/02

  Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P25/30

  for treating abuse or dependence · CPC title